Trimipramine
3564-66-7CC(CN(C)C)CN1c2ccccc2CCc2ccccc21ZSCDBOWYZJWBIY-UHFFFAOYSA-NTrimipramine is a dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant. It has a role as an antidepressant, a xenobiotic and an environmental contaminant. It is a dibenzoazepine and a tertiary amino compound. It is functionally related to an imipramine.
DEA NFLIS-Drug Category -> Antidepressants
Pharmaceuticals -> Used in Switzerland
Pharmaceuticals
Slightly soluble
2.60e-02 g/L
Antidepressants -> Tricyclic antidepressants (TCA)
Breast Feeding; Lactation; Milk, Human; Antidepressive Agents; Antidepressive Agents, Tricyclic
Pharmaceuticals
9.24
9.24
8.5
170.5 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: Antidepressants]
169.17 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
171.2 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
Danger
H301 (97.8%): Toxic if swallowed [Danger Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P272, P273, P280, P301+P316, P302+P352, P304+P340, P305+P354+P338, P317, P319, P321, P330, P332+P317, P333+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 46 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
REACH registered substance: Trimipramine (EC: 212-008-3)
Trimipramine: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an intravenous line and initiate gastric decontamination. A minimum of six hours of observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at any time during this period, extended monitoring is required. (L1712)
N - Nervous system
QN - Nervous system
Trimipramine is a tricyclic antidepressant. It was thought that tricyclic antidepressants work by inhibiting the re-uptake of the neurotransmitters norepinephrine and serotonin by nerve cells. However, this response occurs immediately, yet mood does not lift for around two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. Presynaptic receptors are affected: a1 and b1 receptors are sensitized, a2 receptors are desensitised (leading to increased noradrenaline production). Tricyclics are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain. A precise mechanism for their analgesic action is unknown, but it is thought that they modulate anti-pain opioid systems in the CNS via an indirect serotonergic route. They are also effective in migraine prophylaxis, but not in abortion of acute migraine attack. The mechanism of their anti-migraine action is also thought to be serotonergic.
Hepatic
Hepatic Half Life: 11-18 hrs
6S082C9NDT
TRIMIPRAMINE
Established Pharmacologic Class [EPC] - Tricyclic Antidepressant
Trimipramine is a Tricyclic Antidepressant.
TRIMIPRAMINE
Tricyclic Antidepressant [EPC]
3564-66-7、3564-75-8、739-71-9DTXSID8023715CHEMBL644CHEBI:9738Side effects include agitation, coma, confusion, convulsions, dilated pupils, disturbed concentration, drowsiness, hallucinations, high fever, irregular heart rate, low body temperature, muscle rigidity, overactive reflexes, severely low blood pressure, stupor, vomiting
Trimipramine
1.2
4.9
Maintenance therapy is in the range of 50 to 150 mg/day trimipramine maleate.
Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 50 mg/day, Lowest Therapeutic Dose (LTD): 0.6 mg/kg-day, and Screening Dose: 0.0002 mg/kg-day.
30-Jul-20
Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system.
Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
Use (kg) in Switzerland (2009): >750
For the treatment of depression and depression accompanied by anxiety, agitation or sleep disturbance
Pharmaceuticals
Pharmaceuticals -> Nervous System -> Antidepressants